Milkhaus Veterinary Products has developed a remarkable pipeline of innovative product candidates to treat a number of diseases in dogs, cats, and horses. Milkhaus Vet intends to develop, either by itself or through partners, cost-effective products with the potential to revolutionize the treatment of such intractable diseases as cancer and diabetes in dogs and cats, osteochondrosis in young dogs and horses, and infertility in older mares.

This leading edge technology relies on unique applications of cellular signaling research. Comprised of naturally-occurring molecules, these formulations are already well-characterized but have not previously been used for the therapeutic purposes described. Many of the diseases targeted have limited current treatment options.

Based on pre-clinical and clinical-trial results, the distinctive signature of these therapeutic agents includes:

• Treating diseases for which there are currently limited options;
• Low-dosage efficacy;
• Few, if any, adverse effects.

An effective, cost-saving business profile includes:

• Modest manufacturing costs relative to expected selling prices;
• A network of dedicated professionals;
• All therapeutic agents are protected by patent or patent application for many major, worldwide markets.

The Company's goal is to turn the growing importance of the human-pet bond into an engine for growth for years to come by providing more therapeutic options for the health of companion and athletic animals.